SCHEMBL3427596

SCHEMBL3427596

CC(=O)COc1ccc(C(N)=O)cc1C(F)(F)F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 2/20 0.46
MAPK1 P28482 1/20 0.44
RXRA P19793 2/20 0.44
RXRB P28702 2/20 0.44
RXRG P48443 2/20 0.44
THRA P10827 1/20 0.44
THRB P10828 1/20 0.44
MAOB P27338 3/20 0.43
KMT2A Q03164 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
SLC6A2 P23975 1/20 0.41
SLC6A4 P31645 1/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
CYP2D6 P10635 1/20 0.41
MAPT P10636 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
HTT P42858 1/20 0.41
VNN1 O95497 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3176541 0.84 S1PR1 (0.48) S1PR1MAPK1RXRARXRBRXRG
SCHEMBL12805307 0.81 MRGPRX4 (0.53) S1PR1RXRARXRBRXRGTHRA
SCHEMBL628125 0.80 MAPK1 (0.54) MAPK1KMT2AL3MBTL1KDM4EMEN1
Hydrochloric Acid SCHEMBL7840484 0.79 MAPK1 (0.53) MAPK1KMT2AL3MBTL1KDM4EMEN1
SCHEMBL3433626 0.78 SCN9A (0.44) S1PR1MAPK1RXRARXRBRXRG
SCHEMBL856030 0.77 RXRA (0.70) RXRARXRBRXRGMAOBMRGPRX4
SCHEMBL3428539 0.77 KMT2A (0.41) S1PR1MAPK1RXRARXRBRXRG
SCHEMBL17664021 0.77 RXRA (0.53) S1PR1MAPK1RXRARXRBRXRG
SCHEMBL27480887 0.75 RXRA (0.54) RXRARXRBRXRGMAOBKMT2A
SCHEMBL16380706 0.75 HTR1B (0.49) S1PR1THRATHRBKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642379-B2 Aminoacetonitrile derivatives and their use for controlling parasites on warm-blooded animals NOVARTIS AG (CH) 2010-01-05 US disclosed
US-20080194693-A1 Aminoacetonitrile Derivatives and Their Use for Controlling Parasites on Warm-Blooded Animals NOVARTIS AG (CH) 2008-08-14 US disclosed
EP-1758849-A1 AMINOACETONITRILE DERIVATIVES AND THEIR USE FOR CONTROLLING PARASITES ON WARM-BLOODED ANIMALS Novartis AG (CH) 2007-03-07 EP disclosed
WO-2005121075-A1 AMINOACETONITRILE DERIVATIVES AND THEIR USE FOR CONTROLLING PARASITES ON WARM-BLOODED ANIMALS NOVARTIS AG (CH) 2005-12-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194693-A1 Aminoacetonitrile Derivatives and Their Use for Controlling Parasites on Warm-Blooded Animals MB, ACHE, ADORA2B S1PR1 4559/4885MAPK1 3061/4885RXRA 3011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.